Amgen's Margin Reached 35%. The Stock Still Prices It In.

Amgen reported Q2 FY2026 revenue of $10.05B, up from $9.18B in Q2 FY2025. That is year-over-year growth of 9.5% and marks a new high within the 12-quarter table supplied. Because no company guidance or consensus estimate was provided, the appropriate reference under our methodology is the same quarter one year earlier. On that basis, revenue beat the reference period by approximately $0.87B.

The more important change occurred below the revenue line. Operating income reached $3.51B and operating margin expanded to 35.0%, compared with 28.9% one year earlier. The 6.1-percentage-point increase means operating income grew substantially faster than revenue. It also extends the sequential improvement from a 30.9% margin in Q1 FY2026 and stands well above the 24.7% margin reported for FY2025.

Gross profit was $4.74B, equivalent to a 47.1% gross margin based on the supplied quarterly XBRL values. The year-ago table does not disclose a comparable gross margin; its zero entry represents unavailable data rather than an economic margin of zero. We therefore cannot determine whether gross margin improved year over year or label it a beat. The operating-margin result remains the more useful disclosed measure of quarterly cost leverage.

EPS rose to $4.37 from $2.65, an increase of 64.9%. Free cash flow increased to $3.49B from $1.91B, or 82.7%. Both gains materially exceeded revenue growth, indicating that the quarter's improvement was not limited to the top line. Free cash flow also more than doubled from Q1 FY2026's $1.48B, although quarterly working-capital timing can make sequential cash-flow comparisons volatile.

The balance sheet moved in the right direction. Net debt declined to $43.31B from $48.18B in Q2 FY2025 and $45.28B in Q1 FY2026. Latest point values show $13.99B of cash against $57.30B of debt. The decline is constructive, but the absolute debt burden remains large and continues to influence both risk and valuation.

This quarter improves the quality of Amgen's recent growth. FY2025 revenue increased 10.0% from FY2024, but free cash flow fell to $8.10B from $10.39B. Q2 FY2026 provides a better combination: high-single-digit revenue growth, sharply higher operating profitability and much stronger quarterly free cash flow. The result reduces the concern that growth is being purchased at the expense of near-term cash conversion.

Margin durability is now the central operating question. Amgen's annual operating margin fell from more than 40% in FY2016-FY2019 to 21.7% in FY2024 before recovering to 24.7% in FY2025. The 35.0% Q2 FY2026 result is therefore meaningful, but one quarter does not establish a new normalized margin. A sustained margin near the Q2 level would support a higher earnings base; a return toward the mid-20% annual range would make the current valuation harder to defend.

Returns on invested capital are also recovering. FY2025 ROIC was 11.3%, up from 8.7% in FY2024, while the supplied quarterly measure reached 16.1% in Q2 FY2026. That is the strongest quarterly reading in the provided series. Even so, the calculation is sensitive to operating income and the company's substantial debt load. Continued debt reduction and repeatable operating profits would be required before treating the quarterly figure as a structural improvement.

The quarter therefore strengthens the operating thesis without creating a clear valuation discount. The shares trade at 23.8x trailing EPS of $16.10 and offer a 4.9% trailing free-cash-flow yield on $10.20B of trailing free cash flow. Those figures imply that the market already expects a meaningful portion of the margin recovery to persist. The print was bullish for fundamentals, but only neutral for the risk-adjusted return available at the current price.

With no prior SageNoodle coverage, this article establishes rather than revises fair value. We use a scenario-based trailing P/E framework because trailing EPS is supplied while EBITDA, product-level forecasts and management guidance are not. Each scenario applies an explicit multiple to trailing EPS of $16.10. The multiples are assumptions, not company guidance, and reflect different judgments about margin persistence, cash conversion and balance-sheet risk.

Our base case applies a 23.0x multiple to trailing EPS, producing $370.30 per share, rounded to $370. This assumes that Q2's operating improvement is partly durable but that normalized profitability remains below the quarter's 35.0% operating margin. It also assumes that free cash flow remains near the supplied trailing level and that net debt continues to decline gradually. At $382.61, the shares trade 3.4% above this base value, which falls inside our fairly valued range.

The bear case applies 16.0x trailing EPS for a value of approximately $258. It represents a reversal of margin gains, weaker cash conversion and limited progress reducing debt. The bull case applies 28.0x trailing EPS for a value of approximately $451. That outcome requires the Q2 margin improvement to prove durable, cash flow to remain strong and the balance sheet to continue deleveraging.

We assign probabilities of 25% to the bear case, 50% to the base case and 25% to the bull case. The probability-weighted value is approximately $362, while our published snapshot uses the $370 base-case value as required by our valuation convention. Neither measure offers a 15% margin of safety from the current price. The operational result deserves recognition, but the valuation already asks for continued execution.

The clearest upside risk to our valuation is that Q2's 35.0% operating margin represents a sustainable new earnings level rather than a favorable quarter. If revenue continues growing near the Q2 rate while operating expenses grow more slowly, trailing EPS could rise enough to make the current 23.8x multiple less demanding. Stronger recurring cash conversion would reinforce that outcome and could justify the bull-case multiple.

The main downside risk is margin normalization. Amgen's annual operating margin has varied widely across the supplied history, and FY2025's 24.7% level was well below Q2 FY2026. If the quarterly result benefited from timing or temporary expense patterns, earnings could grow more slowly than the latest print suggests. The absence of product and segment detail in the provided materials makes it impossible to determine which sources of improvement are repeatable.

Leverage is the second constraint. Net debt has declined, but $43.31B remains substantial, and total debt of $57.30B is nearly five times the supplied equity balance of $11.69B. A decline in cash generation would slow deleveraging and reduce financial flexibility. It would also make a premium earnings multiple less appropriate even if reported revenue remained resilient.

Finally, the current price leaves limited room for an ordinary quarter. Revenue, EPS, free cash flow and operating margin all improved materially, yet the shares still stand above our base-case value. The thesis would be proved too cautious if Amgen sustains Q2-level margins and cash flow. It would be proved too optimistic if operating margin falls back toward the FY2025 level while debt reduction stalls. Those are the two variables that subsequent filings need to resolve.